{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T14:47:05Z","timestamp":1793890025974,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","award":["A7160"],"award-info":[{"award-number":["A7160"]}],"id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","award":["A7165"],"award-info":[{"award-number":["A7165"]}],"id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Region Hovedstaden","doi-asserted-by":"publisher","award":["A7272"],"award-info":[{"award-number":["A7272"]}],"id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.atherosclerosis.2023.05.010","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T06:36:07Z","timestamp":1684132567000},"page":"117141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality"],"prefix":"10.1016","volume":"379","author":[{"given":"Takahito","family":"Doi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Langsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib2","first-page":"547","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Genetics, and Biology, Circ Res"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week","volume":"72","author":"Libby","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/eurheartj\/ehl018","article-title":"C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study","volume":"27","author":"Kardys","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1373\/clinchem.2014.234146","article-title":"Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population","volume":"61","author":"Varbo","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/01.RES.0000258023.76515.a3","article-title":"Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory response to tumor necrosis factor-alpha","volume":"100","author":"Ting","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1194\/jlr.M700505-JLR200","article-title":"Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation","volume":"50","author":"Wang","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib11","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1373\/clinchem.2018.294926","article-title":"Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population","volume":"65","author":"Hansen","year":"2019","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib13","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jacc.2022.03.384","article-title":"Elevated remnant cholesterol reclassifies risk of ischemic heart disease and myocardial infarction","volume":"79","author":"Doi","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib14","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib15","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","article-title":"Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications","volume":"62","author":"Martin","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib17","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib18","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ana.22384","article-title":"Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population","volume":"69","author":"Varbo","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012817","article-title":"Positive predictive value of cardiac examination, procedure and surgery codes in the Danish National Patient Registry: a population-based validation study","volume":"6","author":"Adelborg","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgz265","article-title":"Low high-density lipoprotein cholesterol to monitor long-term average increased triglycerides","volume":"105","author":"Langsted","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib21","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/01.ATV.15.4.534","article-title":"Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media","volume":"15","author":"Nordestgaard","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib24","doi-asserted-by":"crossref","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the vulnerable plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib26","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1161\/CIRCRESAHA.115.306427","article-title":"Adaptive response of T and B cells in atherosclerosis","volume":"118","author":"Ketelhuth","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib27","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1006\/bbrc.1999.0543","article-title":"Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes","volume":"257","author":"Kranzhofer","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0009-8981(85)90133-0","article-title":"Raised C-reactive protein levels in serum from smokers","volume":"153","author":"Das","year":"1985","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/CIRCRESAHA.108.177105","article-title":"Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity","volume":"103","author":"Rocha","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib30","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1172\/JCI200319246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib32","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib34","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, the interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib35","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"IL6R Genetics Consortium and Emerging Risk Factors Collaboration, Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib36","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa0707402","article-title":"Genetically elevated C-reactive protein and ischemic vascular disease","volume":"359","author":"Zacho","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib37","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MED.0000000000000799","article-title":"Can remnant cholesterol (triglyceride-rich lipoproteins) reclassify estimated risk of atherosclerotic cardiovascular disease?","volume":"30","author":"Doi","year":"2023","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib41","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1161\/hq1201.100259","article-title":"Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia","volume":"21","author":"Stein","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib43","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib44","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.05.010_bib45","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023002046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023002046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:27:49Z","timestamp":1762187269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023002046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"alternative-id":["S0021915023002046"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.05.010","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual elevated remnant cholesterol and C-reactive protein in myocardial infarction, atherosclerotic cardiovascular disease, and mortality","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117141"}}